Chengdu Kanghua Biological Products Co.,Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Chengdu Kanghua Biological Products Co.,Ltd. - overview
Established
2004
Location
Chengdu, Sichuan, China
Primary Industry
Biotechnology
About
Established in 2004 and based in Chengdu, China, Chengdu Kanghua Biological Products Co. , Ltd. is a biological company that provides biological products for prevention. Kangh has been awarded the honor of Post-Doctoral Innovation Practice Base, Innovative Enterprise, and Sichuan Provincial Creditable Enterprise, and acquired GMP certification by the National Medical Products Administration.
It has a wholly-owned subsidiary Kanghua Animal Protection (Chengdu) Biotechnology. In May 2018, the company closed a strategic investment and it was listed on the Shenzhen Stock Exchange with stock code 300841 in June 2020. The company specializes in the construction of vaccine R&D platforms which have laid out recombinant protein VLP vaccine platform, polysaccharide-protein conjugate vaccine platform, live attenuated vaccine platform, etc. The products include ACYW135 meningococcal polysaccharide vaccine Maikexin and freeze-dried human rabies vaccine HDCV.
The company generates revenue by providing biological products.
Current Investors
Yingke Private Equity
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals
Website
www.kangh.com
Company Stage
Mature
Total Amount Raised
Subscriber access only
Chengdu Kanghua Biological Products Co.,Ltd. - financials
| Fiscal Year Ended | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue (USD) | 261,930,180.6 | 559,467,534.3 | - | - | - |
| % Revenue Growth (YoY) | - | 113.6% | - | - | - |
| EBITDA (USD) | 105,307,200 | 198,906,800 | - | - | - |
| Operating Income (USD) | 90,905,276.3 | 189,628,978.2 | - | - | - |
| Operating Margin | 34.7% | 33.9% | - | - | - |
| % EBITDA Margin | 40.2% | 35.6% | - | - | - |
| NET Income (USD) | 74,457,944.8 | 154,139,677.6 | - | - | - |
| % Net Margin | 28.4% | 27.6% | - | - | - |
Chengdu Kanghua Biological Products Co.,Ltd. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Add-on | Completed | NanoRibo | - |
Displaying 1 - 1 of 1
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.